Since the passage of the Biosimilar User Fee Act (BsUFA) in 2012, user fees have played an important role in expediting the process for the review of biosimilar products.
Similar Posts
Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies
Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical StudiesFDA approves new treatment for acromegaly, a rare endocrine disorder
The U.S. Food and Drug Administration (FDA) approved Palsonify (paltusotine) tablets to treat adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option.Withdrawn and Expired Guidances | Drugs
Withdrawn and Expired Guidances | DrugsAnhui Hanbon Daily Chemical Co., Ltd. – 708903 – 08/11/2025
CGMP/Finished Pharmaceuticals/AdulteratedFind Information about a Drug
Information on FDA-approved drugs released for sale on the market, such as dosage, side effects, and disposal methodsMeamo – 11/03/2025
Unapproved New Drugs/Misbranded/Botox